Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA advisory committee meeting scheduled for July 29, 2026, to review Deramiocel BLA for Duchenne muscular dystrophy.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA advisory committee meeting scheduled for July 29, 2026, to review Deramiocel BLA for Duchenne muscular dystrophy
- Deramiocel regulatory review enters a key public milestone ahead of potential approval
- PDUFA target action date remains August 22, 2026, preserving the expected FDA decision timeline
- Advisory committee recommendation may materially influence approval expectations and CAPR valuation
Item EX-99.1 · Exhibit EX-99.1
- FDA advisory committee review scheduled for July 29, 2026, creating a key regulatory catalyst for Deramiocel
- BLA remains on track for August 22, 2026 PDUFA action date, implying approval decision shortly after committee review
- Application supported by positive Phase 3 HOPE-3 results across skeletal, cardiac, and other Type I error-controlled endpoints
- Approval could unlock first-in-class DMD therapy potential and possible Priority Review Voucher eligibility
- Advisory committee recommendation is nonbinding, leaving regulatory, safety, manufacturing, and approval risks ahead
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.